Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics, maintaining a $64 price target.
September 20, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on PTC Therapeutics, maintaining a $64 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $64 price target by a reputable analyst suggests positive sentiment and potential upside for PTC Therapeutics, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100